As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Polaryx Therapeutics, Inc. The largest reported stake is Mstone Partners Healthcare Limited's, at 48%. One filing is on record since February 5, 2026 (Schedule 13D, February 5, 2026).
Sell to companies like Polaryx Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Polaryx Therapeutics, Inc. has 1 Schedule 13D or 13G filing on record since 2026-02-05. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share ("common stock"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Mstone Partners Healthcare Limited | 48% | 22,452,954 | SCHEDULE 13D, 2026-02-05 | 2026-01-29 |
Holding shares or following this stake? See who's behind Polaryx Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Polaryx Therapeutics, Inc. and the records around it.
Polaryx Therapeutics, Inc. elsewhere on the record
- Crowdfunding filing Oct 2025
- Who owns it
Watch Polaryx Therapeutics, Inc.
Get an email when Polaryx Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Polaryx Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Polaryx Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Polaryx Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Mstone Partners Healthcare Limited
The Reporting Persons own 48.0% of the Company in the aggregate, based on 47,343,297 shares of Common Stock outstanding as of January 12, 2026. Mr. Yang serves as Chief Executive Officer and as a member of the board of directors of the Company (the "Board"), and, in such capacity, may have influence over the corporate activities of the Company, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the Board with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Company or other persons.Item 4 of the SCHEDULE 13D filed 2026-02-05
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-05 | Mstone Partners Healthcare Limited | 48% | SCHEDULE 13D |
Also on the record for Polaryx Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 31, 2025 | Crowdfunding filing, Form C-U | $15K target | Crowdfunding | Source |
| October 27, 2025 | Crowdfunding filing, Form C-U | $15K target | Crowdfunding | Source |
| October 1, 2025 | Crowdfunding filing, Form C/A | $15K target | Crowdfunding | Source |
| September 3, 2025 | Crowdfunding filing, Form C | $15K target | Crowdfunding | Source |
Tools for this story
Each opens in a new tab, filled in for Polaryx Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.